ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.02
+0.22 (4.58%)
Mar 10, 2026, 4:08 PM HKT
-11.93%
Market Cap 2.07B
Revenue (ttm) 134.60M
Net Income (ttm) -331.67M
Shares Out 431.51M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,406,200
Average Volume 1,485,020
Open 4.68
Previous Close 4.80
Day's Range 4.68 - 5.30
52-Week Range 3.43 - 16.80
Beta 0.97
RSI 59.85
Earnings Date Mar 25, 2026

About HKG:1541

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 195
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1541
Full Company Profile

Financial Performance

In 2024, HKG:1541's revenue was 79.54 million, an increase of 933.61% compared to the previous year's 7.70 million. Losses were -315.86 million, -16.76% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.